{"name":"AnPac Bio-Medical Science","slug":"anpac","ticker":"ANPC","exchange":"NASDAQ","domain":"anpacbio.com","description":"AnPac Bio-Medical Science is a biotechnology company focused on cancer diagnostics and therapeutics. The company's top products include its CDT-based cancer screening and diagnosis platform. AnPac Bio-Medical Science is a relatively small player in the oncology diagnostics market, but its innovative technology has the potential to disrupt the industry. The company is headquartered in China and has a growing presence in the US.","hq":"Lishui, China","founded":0,"employees":"","ceo":"Chris Yu","sector":"Diagnostics / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":5000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"AnPac Bio-Medical Science Reports 2023 Year-End Financial Results","summary":"AnPac Bio-Medical Science reported its 2023 year-end financial results, with revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"AnPac Bio-Medical Science Partners with Leading Cancer Research Institute","summary":"AnPac Bio-Medical Science announced a partnership with a leading cancer research institute to develop new cancer diagnostic technologies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQVzRuMUR2eU9JMElrVHpKOUlaWTJJRmVYZnVlYnhhWElia05seU95a3JIclVDNkktSGM5TnE3Sy03WlRsQThsU0MxRm5VUGFLbnJ1dVlub0NPejRfZnRPZVRCOUJsT2pvd01oa1VuRXFuci1iQ3J4V01ZbXc5eEtRS2F4YzE4VmVnR2I5Z0RYOFloNERpdUdaN3VLOFBraGNCU3VLdWY0bFE2ZnBJWmstdW9TaFpRQldtcTQ5Wk1IZmpUendwZDVLTTJhMVRfa1FqQlE?oc=5","date":"2022-10-14","type":"pipeline","source":"Investing.com UK","summary":"Why Otonomy Shares Dipped By Around 54%; Here Are 67 Biggest Movers From Yesterday By Benzinga - Investing.com UK","headline":"Why Otonomy Shares Dipped By Around 54%; Here Are 67 Biggest Movers From Yesterday By Benzinga","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBLNTdKT3NKaEZjbzFhSzNtOEJDUTVaVDlnREFNU1RqWmtPN3JvY3dURXJBZHRyNmtveW5GQzhuaDFRWFZ1TDc2ZFFyMXk2US1s?oc=5","date":"2021-09-15","type":"pipeline","source":"The Motley Fool","summary":"Idera Pharmaceuticals - IDRA - Stock Price & News - The Motley Fool","headline":"Idera Pharmaceuticals - IDRA - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQ2p3M2syYjJoV2NqWHpTUzFIUGNtVUxLM0xRdXdqLTNDNGRNWEhudVZRNkFPdGI0bUtfYzJuM2ZINGZaLXZiSmlOTFloNlZBbngySDh2eDFDbHROMThCaGIxaUtEdHBCZ1RhOEphRzUxYk5LTXhJRkJTU1N0bkZBRDUzaElNel8xQXEtZUJQNmFfb0lKeGk2S0g5OHBhQzI4SUdUb0VDaF9tUElTRWV6VDM3djZqTFlK?oc=5","date":"2021-06-18","type":"pipeline","source":"InvestorPlace","summary":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace","headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2020-04-30","type":"pipeline","source":"simplywall.st","summary":"Can We See Significant Insider Ownership On The AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Share Register? - simplywall.st","headline":"Can We See Significant Insider Ownership On The AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Share Register?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Guardant Health","Foundation Medicine","Invitae"],"therapeuticFocus":["Oncology","Cancer Diagnostics"],"financials":null,"yahoo":null}